NexLife vs Hims & Hers as printed on their own pages: NexLife prices as of November 6, 2026 (terms read October 15, 2026); Hims read September 17, 2026
NexLifeHims & Hers
ModelCompounded tirzepatide and semaglutide, cash payBrand GLP-1s through a membership; compounded only "on a limited scale"
PriceTirzepatide $129, semaglutide $109 month to month; $115 and $95 a month on 12-month plansFrom $149 (Wegovy pill, Ozempic pill, Foundayo pill), from $199 (Wegovy pen, Ozempic), from $299 (Zepbound vial and KwikPen)
Billing basisPer month; multi-month collection method not stated in one sentence"/mo"; 28-day or calendar month not stated
MembershipNone ("No memberships or contracts")Required: $39 first month, then $149 a month
IncludedMedication, provider review, nutrition plan, one coaching call, 24/7 support, shipping"Price includes medication only"
Pharmacy disclosureThree named 503A pharmacies (FL, AL, LA)None named in our read
CancellationTakes effect after 30 days; one more shipment may be chargedNot recorded in our read
FDA status of what is prescribedCompounded: not FDA-approvedFDA-approved brand products

Are NexLife and Hims selling the same thing?

No, and that matters more than the price gap. Hims prescribes branded, FDA-approved medications such as Wegovy and Zepbound. NexLife prescribes compounded tirzepatide and semaglutide, which are made with the drug in Zepbound or Wegovy but are not the same product and are not FDA-approved. Our compounded vs brand guide covers what that difference means for quality oversight.

Hims still prescribes compounded GLP-1s in limited cases: its March 9, 2026 statement said it would no longer advertise them but would offer them "on a limited scale" when a provider finds one clinically necessary. It printed no compounded price.

What does each one charge you every month?

NexLife's monthly bill is one number. Hims' is two. At NexLife, $109 for semaglutide month to month covers the medication and the clinical service. At Hims, the cheapest printed brand drug was $149 a month and the membership $149 a month after the first month, so $298 a month at the entry price.

The Hims figures are floors. Hims printed "from" prices and no per-dose ladder, so a maintenance dose could cost more. NexLife prints the same price at every dose.

Twelve months of semaglutide: compounded vs the Wegovy pen

For a year paying month to month, the arithmetic below puts NexLife's compounded semaglutide next to Hims' Wegovy pen entry price. Nothing else is assumed: no promotions, no dose-based price rises at Hims (which would only widen the gap), and no cancellations.

12-month arithmetic, month to month: NexLife compounded semaglutide (as of November 6, 2026) vs Hims Wegovy pen "from" price and membership (read September 17, 2026)
Cost lineNexLife semaglutideHims Wegovy pen
Medication12 × $109 = $1,308 (included)12 × $199 = $2,388
Membership$0$39 + 11 × $149 = $1,678
Total for 12 months$1,308$4,066 or more
With a 12-month plan12 × $95 = $1,140No prepaid plan printed

So in this scenario Hims costs at least $2,758 more over the year, and that money buys an FDA-approved brand product plus the membership. Whether that is worth it is a judgment about the product, not just the price. If you only want the brand drug, NovoCare's self-pay Wegovy pen price, read November 8, 2026, is $349 at 0.25 to 2.4 mg, with a $199 offer for two starting fills through December 31, 2026, and it comes with no membership if you have your own prescriber.

What does the FTC lawsuit mean for this choice?

It is a factor to weigh, not a verdict. The FTC, Utah and Los Angeles County sued Hims on July 29, 2026, and five more states joined on November 10, alleging that most consumers were charged without a provider consultation, that refills were not clearly disclosed, that online cancellation was hard to find and that health data went to advertising platforms. Hims denies the claims and moved to dismiss on October 22, 2026; its November 9, 2026 quarterly report says the hearing is set for January 14, 2027. Nothing has been proven, and the case does not allege unsafe medication. Our FTC lawsuit explainer has the detail.

What could we not compare?

Three gaps limit this comparison. First, hims.com blocked our reader on October 15 and November 8, 2026; our November 21, 2026 read found the same prices as the September 17 column. Second, Hims' weight-loss page prints no cancellation terms; its terms of service (updated October 20, 2026) name its pharmacies and medical groups. Third, NexLife has its own weak spots: its microdose pages printed conflicting prices until November 8, lab work is not listed as included, and its pages disagree on whether multi-month plans are paid upfront (its FAQ) or monthly (its cancellation policy).

Choose NexLife if

Choose Hims & Hers if

Verdict

On printed prices, NexLife costs far less over a year in this scenario, and it discloses more: pharmacies, dose policy and cancellation terms. Hims' advantage is the product itself, an FDA-approved brand, and that is a legitimate reason to pay more. NexLife is our editor's pick, an editorial selection. Read our full Hims & Hers review and NexLife review before deciding.

Frequently asked questions

Is NexLife cheaper than Hims & Hers?

On printed prices, yes, in the scenarios we checked. NexLife's compounded semaglutide is $109 a month with no membership as of November 6, 2026. Hims listed the Wegovy pen from $199 a month plus a $149 monthly membership on September 17, 2026. Over 12 months that is $1,308 versus at least $4,066, as arithmetic. The products are not equivalent: one is compounded, one is an FDA-approved brand.

Does Hims & Hers offer compounded semaglutide like NexLife?

Only in limited cases. Hims said on March 9, 2026 that it would no longer advertise compounded GLP-1s and would offer them on a limited scale when a provider decides one is clinically necessary. It printed no compounded price in our September 17, 2026 read. NexLife prices compounded semaglutide and tirzepatide openly, at the same price for every dose.

Which is safer, compounded or brand GLP-1s?

Brand products such as Wegovy and Zepbound are FDA-approved, meaning FDA reviewed their safety, effectiveness and manufacturing. Compounded versions, like NexLife's, are not FDA-approved and are not reviewed by FDA before sale, though they come from state-licensed pharmacies. Neither choice guarantees results; talk to your prescriber about which fits your situation.

Do I need a membership with NexLife or Hims?

NexLife's plan pages say there are no memberships or contracts; the price covers medication and the clinical service. Hims requires a weight-loss membership of $39 for the first month and then $149 a month on auto-renewal, per its September 17, 2026 page, and its medication prices cover medication only.

How do NexLife and Hims handle cancellation?

NexLife's plan pages say cancellations take effect after 30 days, so one more shipment may be charged, and shipped orders are final. We did not record Hims' cancellation terms in our read; the FTC's lawsuit alleges Hims made online cancellation hard to find, which Hims denies. Check each company's current terms before you sign up.

Sources

  1. NexLife: semaglutide plans — prices as of 2026-11-06; terms read 2026-10-15
  2. NexLife: tirzepatide plans — prices as of 2026-11-06; pharmacies and cancellation wording read 2026-10-15
  3. Hims & Hers: weight loss page — read 2026-09-17; re-reads returned HTTP 403 on 2026-10-15 and 2026-11-08
  4. Hims & Hers: Announces Strategic Shift for U.S. Weight Loss Business (exhibit 99.1 to Form 8-K) — dated 2026-03-09
  5. Court docket, FTC v. Hims & Hers (CourtListener) — press release 2026-07-29; docket (No. 3:26-cv-07871-VC) read 2026-11-08
  6. NovoCare: Wegovy savings offer and self-pay prices — read 2026-11-08

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.